Search clinical trials for: Valsartan (Diovan)

Total 534 results

Novartis

Completed

Efficacy and Safety of Aliskiren in Patients With Mild to Moderate Hypertension During Exercise

Hypertension

Singapore, Hungary, Czech Republic, United Kingdom
Brigham and Women's Hospital
Novartis Pharmaceuticals

Withdrawn

Comparing ARNI With ACE Inhibitor on Endothelial Function (PARADOR)

Heart Failure With Reduced Ejection Fraction
IlDong Pharmaceutical Co Ltd

Completed

A Bioequivalence Study Comparing Cilnidipine/Valsartan Combination With Coadministration of Cilnidipine and Valsartan (IDCV)

Hypertension
Novartis

Completed

Safety and Efficacy of Valsartan and Amlodipine Combined and Alone in Patients With Hypertension.

Hypertension

Germany
Trinity Hypertension & Metabolic Research Institute
Allergan Sales, LLC

Completed

Efficacy and Safety of Valsartan and Nebivolol/Valsartan in Hypertensive Patients With LVH (BVreduce)

Blood Pressure | Hypertrophy, Left Ventricular | Hypertension Complicated

United States
Novartis

Completed

Safety and Efficacy of Valsartan and Amlodipine Combined and Alone in Hypertensive Patients

Hypertension

United States, Germany
LG Life Sciences

Completed

Efficacy and Safety of Lercanidipine and Valsartan in Patients With Essential Hypertension

Essential Hypertension

Korea, Republic of
Novartis Pharmaceuticals

Completed

Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction (PARAGON-HF)

Heart Failure With Preserved Ejection Fraction

China, Germany, United States, Colombia, South Africa, Italy, Austria, Belgium, Croatia, Romania, Taiwan, Japan, Netherlands, Denmark, France, Israel, Spain, Switzerland, Korea, Republic of, Argentina, Canada, United Kingdom, Bulgaria, Gree... and more
University of Maryland, Baltimore
Medtronic

Withdrawn

Sacubitril-valsartan Versus Usual Anti-hypertensives in LVAD

Hypertension | Congestive Heart Failure
Novartis

Terminated

Antialbuminuric Effects of Valsartan and Lisinopril

Hypertension | Early Diabetic Nephropathy

Switzerland
Novartis Pharmaceuticals

Completed

A Study to Evaluate the Effect of LCZ696 on Aortic Stiffness in Subjects With Hypertension

Hypertension

Germany, Switzerland, United Kingdom
Farma de Colombia SA

Completed

Efficacy/Safety Study of Valsartan and Chlorthalidone Conjugate Treatment Compared to Simple Treatment for Hypertension

Hypertension

Colombia, Ecuador
Oslo University Hospital

Recruiting

Infectious Pseudochromdrosis Caused by Bacillus Cereus (Blue sweat)

Infectious Disease | Bacterial Overgrowth | Pigment Deposition

Norway
Novartis Pharmaceuticals

Completed

Sodium Excretion of LCZ696 in Patients With Hypertension; Heart Failure and Healthy Volunteers

Hypertension

Russian Federation
Novartis Pharmaceuticals

Completed

LCZ696 Compared to Valsartan in Patients With Chronic Heart Failure and Preserved Left-ventricular Ejection Fraction

Chronic Heart Failure

Poland, Netherlands, United States, Argentina, Spain, Singapore, Italy, India, Russian Federation, Canada, Romania, Brazil, Venezuela, Germany
Novartis Pharmaceuticals

Completed

Efficacy and Safety of LCZ696A in Patients With Essential Hypertension

Hypertension

Spain, Italy, Netherlands, United States, Denmark, Taiwan, Argentina, Germany, Russian Federation, Slovakia, Canada, Hungary, Latvia, Lithuania, Poland, Finland, France, Sweden
Asan Medical Center
Novartis

Completed

Pharmacological Reduction of Functional, Ischemic Mitral REgurgitation (PRIME)

Mitral Valve Insufficiency | Left Ventricular Dysfunction

Korea, Republic of
Assaf-Harofeh Medical Center

Unknown

Ocsaar and CYP2C9 Ploymorphism, Is There a Connection Between Pharmacokinetics, Pharmacodynamics and Pharmacogenetics?

Hypertension
Novartis Pharmaceuticals

Completed

Study of Effects of Sacubitril/Valsartan vs. Enalapril on Aortic Stiffness in Patients With Mild to Moderate HF With Reduced Ejection Fraction (EVALUATE-HF)

Heart Failure and Reduced Ejection Fraction

United States
RenJi Hospital

Unknown

Early Treatment of ARNI on Myocardial Remodeling and Progress

Myocardial Infarction

China
Novartis Pharmaceuticals

Completed

Study of Efficacy and Safety of CVAA489 in Hypertensive Patients

Essential Hypertension

Turkey
Novartis Pharmaceuticals

Completed

An 8-week Study to Evaluate the Dose Response of AHU377 in Combination With Valsartan 320 mg in Patients With Mild-to-moderate Systolic Hypertension

Systolic Hypertension

United States, Spain, Hungary, Korea, Republic of, Argentina, India, Slovakia, Canada, Romania
National Medical Research Center for Cardiology...
Ministry of Health of Russian Federation

Recruiting

LCZ696 in Advanced LV Hypertrophy and HFpEF

Heart Failure | Essential Hypertension

Russian Federation
HK inno.N Corporation

Unknown

Study to Evaluate the Safety and Efficacy of CJ-30061 in Hypertensive Patients With Hyperlipidemia

Hypertension | Hyperlipidemia

Korea, Republic of
Prince of Songkla University

Recruiting

PK of Meropenem in Patients on Plasma Exchange

Autoimmune Diseases

Thailand
Nantou Christian Hospital

Completed

Effect of Adding Renin-Angiotensin System Inhibitors to Standard Antidiabetic Therapy on Glycemic Control in Patients With Type 2 Diabetes Ellitus

Diabetes Mellitus, Type 2

Taiwan
Federico II University

Completed

Efficacy and Safety of Valsartan Plus Hydrochlorothiazide in Patients With Slight Hypertension and Target Organ Damage

Hypertension | Ventricular Remodeling | Erectile Dysfunctions

Italy
University of Pavia

Unknown

Valsartan and Amlodipine Compared to Losartan and Amlodipine in Hypertensive Patients

Essential Hypertension

Italy
University Medical Centre Ljubljana

Completed

Preventive Arterial Wall Phenotype and Low-dose Fluvastatin/Valsartan Combination (AGE-ZT)

Atherosclerosis
Novartis

Completed

Long Term Study of Valsartan and Amlodipine in Patients With Essential Hypertension (Extension to Study CVAA489A1301)

Hypertension

Japan
Nantes University Hospital

Terminated

Anti-Proteinuric Response to ACEI, ARB and Diuretics Combination.

Heavy Proteinuria

France
The Cleveland Clinic

Recruiting

Safety and Efficacy of ARNI After LVAD ImplanT (SEAL-IT) Study (SEAL-IT)

Stage D Heart Failure

United States
Genuine Research Center, Egypt
Pharmacare PLC, Palestine

Completed

A Bioequivalence Study of Amlodipine / Valsartan From Amlodipine/Valsartan 10/160 Tablets (Pharmacare, Palestine) and Exforge Tablets (Novartis Pharma, USA)

Healthy

Egypt
Saitama Medical University

Completed

Effects of Angiotensin Receptor Antagonist on Prohibiting Cardiovascular Events on Hemodialysis Patients

Cardiovascular Disease
Second Affiliated Hospital of Wenzhou Medical University

Unknown

A Bioequivalence Study of Valsartan / Amlodipine From Valsartan and Amlodipine Tablets (Hua Yuan Pharmaceutical LLC, China) and Valsartan and Amlodipine Tablets (Ⅰ) (Novartis Pharma Schweiz AG, Switzerland) (ABSVAFVATVAT)

Healthy

China
Novartis

Completed

The Effects of Moderate vs. Aggressive Treatment With Valsartan + Amlodipine on Patients With Hypertension Uncontrolled by Angiotensin-Receptor Blocker (Herein, ARB) Monotherapy (EXTRA)

Hypertension

United States
TSH Biopharm Corporation Limited

Completed

PMS Study of Amlodipine/Valsartan for the Treatment of Hypertension

Essential Hypertension

Taiwan
Mario Negri Institute for Pharmacological Research
Agenzia Italiana del Farmaco

Completed

Preventing ESRD in Overt Nephropathy of Type 2 Diabetes (VALID)

Diabetes

Italy, Slovenia
University Medical Centre Ljubljana

Completed

Post- Myocardial Infarction Arterial Wall Improvement by Low-dose Fluvastatin and Valsartan

Myocardial Infarction

Slovenia
Shanghai Jiao Tong University School of Medicine

Recruiting

Sacubitril/Valsartan Versus Amlodipine in Hypertension and Left Ventricular Hypertrophy.

Hypertension | Left Ventricular Hypertrophy

China
Novartis Pharmaceuticals

Completed

Safety, Tolerability, and Efficacy of Once Daily Amlodipine/Valsartan 5/80 as Compared to Amlodipine/Valsartan 5/40 or to Amlodipine 5 mg Monotherapy in Patients 65 Years of Age and Older With Essential Hypertension

Hypertension

Czech Republic, Finland, France, Germany, Hungary, Italy, Poland, Slovakia, Spain, Sweden
Merck Sharp & Dohme LLC
Centocor, Inc.

Completed

Investigation of 9 Consecutive Infusions of Remicade for Psoriatic Arthritis in Austria (Study P04264)

Arthritis, Psoriatic
Brigham and Women's Hospital

Active, not recruiting

Prospective Monitoring of Angiotensin Receptor Neprilysin Inhibitor in Older Adults With Heart Failure and Frailty

Frailty | Heart Failure, Systolic

United States
Mario Negri Institute for Pharmacological Research
Agenzia Italiana del Farmaco

Completed

Preventing Microalbuminuria in Type 2 Diabetes (VARIETY)

Diabetes

Italy
HK inno.N Corporation

Completed

Phase I Study to Compare the Safety, Pharmacokinetic Profiles of CJ Amlodipine/Valsartan 10/160mg and Novartis Exforge 10/160mg

Healthy

Korea, Republic of
HK inno.N Corporation

Completed

Study to Evaluate the Safety and Efficacy of CJ-30060 in Hypertensive Patients With Hyperlipidemia

Hypertension With Hyperlipidemia
Yonsei University

Completed

Randomized, Open Labeled Clinical Trial to Compare the Effectiveness of Amlodipine/Valsartan vs Hydrochlorothiazide/Telmisartan on Glucose Tolerance in Patients With Hypertension With Metabolic Syndrome

Hypertension

Korea, Republic of
Medical Center Alkmaar

Unknown

Dipeptide Alanyl Glutamine and Postoperative Insulin Resistance in Colon Carcinoma Patients (AIRCo)

Colon Carcinoma

Netherlands
Damanhour University

Completed

Pharmacokinetic Interactions of Valsartan and Hydrochlorothiazide (Double Doses) (PKVH PART II)

Healthy Normotensive Participants
Novartis

Completed

Valsartan/Hydrochlorothiazide Combination in Hypertensive Patients Not Controlled With Valsartan Alone

Hypertension

Switzerland, Germany

3

Subscribe